At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 23 enrolled
Drug / intervention
MEDI4736 in combination with nab-paclitaxel and gemcitabine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase Ib and II Open-Label, Multi-Center Study of MEDI4736 Evaluated in Different Combinations in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
In Brief
A Phase 2 clinical trial evaluating MEDI4736 in combination with nab-paclitaxel and gemcitabine and MEDI4736 in combination with AZD5069 for Metastatic Pancreatic Ductal Adenocarcinoma. Completed, enrolled 23 participants across 7 sites in 2 countries.
Detailed Summary
A Phase Ib and II Open-Label, Multi-Center Study of MEDI4736 Evaluated in Different Combinations (with chemotherapy or AZD5069) in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedOct 2015
Enrollment StartMar 2016
Primary CompletionJul 2018
TodayJul 2026
First PostedOct 22, 2015
Enrollment StartMar 25, 2016
Primary CompletionJul 9, 2018
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 10.7 years ago
Interventions
MEDI4736 in combination with nab-paclitaxel and gemcitabinedrug
MEDI4736 in combination with nab-paclitaxel + gemcitabine chemotherapy regimen via IV infusion
MEDI4736 in combination with AZD5069drug
MEDI4736 via IV infusion and oral AZD5069